During its 148th session, the European Pharmacopoeia Commission adopted eight new monographs for inclusion in the European Pharmacopoeia, amongst them two active substances (Imatinib mesilate (2736) and Rosuvastatin calcium (2631)) still under patent protection which were elaborated in close collaboration with the respective innovator companies (P4 procedure).